Ann Lab Med.  2015 Nov;35(6):651-653. 10.3343/alm.2015.35.6.651.

Straightforward Identification of Masked Polycythemia Vera Based on Proposed Revision of World Health Organization Diagnostic Criteria for BCR-ABL1-Negative Myeloproliferative Neoplasms

• Chu D
• Cho YU
• Jang S
• Seo EJ
• Park CJ

• KMID: 2363272
• DOI: http://doi.org/10.3343/alm.2015.35.6.651

Abstract

No abstract available.

MeSH Terms

Adult
Biomarkers, Tumor/genetics
Bone Marrow/pathology
Calreticulin/genetics
Erythropoietin/blood
Female
Fusion Proteins, bcr-abl/*genetics
Hematocrit
Hemoglobins/analysis
Humans
Janus Kinase 2/genetics
Male
Middle Aged
Mutation
Myeloproliferative Disorders/*diagnosis/genetics
Polycythemia Vera/*diagnosis/genetics
Receptors, Thrombopoietin/genetics
Thrombocythemia, Essential/diagnosis
World Health Organization
Biomarkers, Tumor
Calreticulin
Erythropoietin
Fusion Proteins, bcr-abl
Hemoglobins
Janus Kinase 2
Receptors, Thrombopoietin

Figure

• 

  Fig. 1 Bone marrow histomorphology of essential thrombocythemia (ET) and masked polycythemia vera (PV). (A) Bone marrow morphology of ET shows normocellular marrow with an increased number of large and mature megakaryocytes. Note the hyperlobulated megakaryocytes without significant pleomorphism (bone marrow biopsy, hematoxylin and eosin [H&E] stain, ×200). (B) Bone marrow morphology of masked PV (patient 1) shows a trilineage proliferation. Note the higher cellularity compared with that in (A) and an increased number of megakaryocytes displaying cytologic pleomorphism with mild atypia (bone marrow biopsy, H&E stain, ×200).

Reference

1. Thiele J, Kvasnicka HM, Orazi A, Tefferi A, Birgegard G, Gisslinger H, et al. Polycythemia vera. In : Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC;2008. p. 40–43.

2. Shih LY, Lee CT. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood. 1994; 83:744–748. PMID: 8298136.

3. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia vera. Leukemia. 2014; 28:1191–1195. PMID: 24352199.

4. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision for WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014; 28:1407–1413. PMID: 24441292.

5. Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014; 89:52–54. PMID: 23996471.

6. Barbui T, Thiele J, Carobbio A, Guglielmelli P, Rambaldi A, Vannucchi AM, et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am J Hematol. 2014; 89:588–590. PMID: 24535932.

7. Barbui T, Thiele J, Carobbio A, Gisslinger H, Finazzi G, Rumi E, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol. 2014; 89:199–202. PMID: 24166817.

8. Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2013; 122:1881–1886. PMID: 23900239.